Condition: Kidney Cancers

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT07590310

Sponsor: Peking University Cancer Hospital & Institute

Phase: Early Phase 1

Eligibility:

• Age: minimum 18 Years maximum 75 Years
• Gender: All

Inclusion Criteria:

• -Hematological, hepatic, and renal functions meeting the following criteria: Complete Blood Count: WBC ≥4.0×10⁹/L or Neutrophils ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥90 g/L; Coagulation: PT or APTT ≤1.5 × ULN (Upper Limit of Normal); Hepatic Function: T-Bil ≤1.5 × ULN; ALT/AST ≤2.5 × ULN (or ≤5 × ULN for subjects with liver metastases); ALP ≤2.5 × ULN (or ≤4.5 × ULN for subjects with bone or liver metastases); Renal Function: BUN ≤1.5 × ULN, SCr ≤1.5 × ULN. Normal cardiac function;
• Expected survival ≥12 weeks;
• Good compliance with follow-up;
• At least one measurable target lesion according to RECIST 1.1 criteria;
• Women of childbearing potential (aged 18-49) must have a negative pregnancy test within 7 days prior to the examination. Male and female patients of childbearing potential must agree to use effective contraception to prevent pregnancy during the study and for 3 months after the examination;
• Patients for whom the clinician recommends a PET/CT examination for tumor diagnosis and staging;
• Patients are fully capable of understanding the study, voluntarily agree to participate, and provide written informed consent.

Exclusion Criteria:

• Severe abnormalities in hepatic, renal, or hematological function;
• Patients planning for pregnancy;
• Pregnant or lactating women;
• Inability to lie flat for 30 minutes;
• Refusal to participate in this clinical study;
• Presence of claustrophobia or other psychiatric disorders;
• Any other condition deemed unsuitable for participation by the investigator.

View trial on ClinicalTrials.gov